Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis

83Citations
Citations of this article
146Readers
Mendeley users who have this article in their library.

Abstract

Background Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat anemia in patients undergoing hemodialysis, the relative mortality risks associated with use of different types of ESAs are unknown. Methods To compare the mortality risk associated with use of short-acting ESAs versus long-acting ESAs, we conducted a nationwide cohort study of 194,698 hemodialysis patients in Japan who received either a short-acting (epoetin α/β or epoetin k) or a long-acting (darbepoetin or epoetin β pegol) ESA. Study outcomes were 2-year all-cause and cause-specific mortality. In addition to Cox proportional hazards models, we performed an instrumental variable analysis in which facility-level long-acting ESA prescription rates were taken as the instrumental variable. Results During the 2-year follow-up period, 31,557 deaths occurred. In a multivariable Cox model, long-acting ESA users had a 13% higher rate of deaths compared with short-acting ESA users, a significant difference (P<0.001). Similar results were obtained in other analyses. This difference in risk was pronounced among patients receiving high doses of ESA (for whom the adjusted 2-year number needed to harm for death was 30.8). Long-acting ESA use was associated with an increased rate of death from cardiovascular diseases, infection, and malignancies. In the instrumental variable analysis, long-acting ESA users remained at a significantly higher risk of death. Compared with anemic (hemoglobin 9.0–9.9 g/dl) short-acting ESA users, long-acting ESA users who achieved more optimal hemoglobin levels (10.0–10.9 g/dl) showed a higher mortality rate. Conclusions Among patients undergoing hemodialysis, use of long-acting ESAs might be associated with a higher risk of death than use of short-acting ESAs.

References Powered by Scopus

Correction of anemia with epoetin alfa in chronic kidney disease

2476Citations
N/AReaders
Get full text

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1993Citations
N/AReaders
Get full text

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1904Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Hypoxia signaling in human health and diseases: implications and prospects for therapeutics

194Citations
N/AReaders
Get full text

Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents

166Citations
N/AReaders
Get full text

Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin

95Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sakaguchi, Y., Hamano, T., Wada, A., & Masakane, I. (2019). Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. Journal of the American Society of Nephrology, 30(6), 1037–1048. https://doi.org/10.1681/ASN.2018101007

Readers over time

‘19‘20‘21‘22‘23‘24‘25010203040

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 31

50%

Researcher 18

29%

Professor / Associate Prof. 8

13%

Lecturer / Post doc 5

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 57

70%

Pharmacology, Toxicology and Pharmaceut... 12

15%

Nursing and Health Professions 10

12%

Agricultural and Biological Sciences 3

4%

Save time finding and organizing research with Mendeley

Sign up for free
0